{{Rsnum
|rsid=743572
|Gene=CYP17A1
|Chromosome=10
|position=104597152
|Orientation=plus
|GMAF=0.4201
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=131
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}
{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 39.8 | 44.2 | 15.9
| HCB | 17.6 | 48.5 | 33.8
| JPT | 30.1 | 52.2 | 17.7
| YRI | 51.7 | 38.8 | 9.5
| ASW | 33.3 | 50.9 | 15.8
| CHB | 17.6 | 48.5 | 33.8
| CHD | 15.6 | 56.9 | 27.5
| GIH | 35.6 | 48.5 | 15.8
| LWK | 53.6 | 34.5 | 11.8
| MEX | 36.8 | 47.4 | 15.8
| MKK | 37.8 | 48.1 | 14.1
| TSI | 37.3 | 49.0 | 13.7
| HapMapRevision=28
}}
{{PMID Auto
|PMID=19415745
|Title=Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women
}}

{{PMID Auto
|PMID=18682255
|Title=Arsenic metabolism is influenced by polymorphisms in genes involved in one-carbon metabolism and reduction reactions
}}

{{PMID Auto
|PMID=20432167
|Title=Dietary isoflavone intake, polymorphisms in the CYP17, CYP19, 17beta-HSD1, and SHBG genes, and risk of breast cancer in case-control studies in Japanese, Japanese Brazilians, and non-Japanese Brazilians
}}

{{PMID Auto
|PMID=21824047
|Title=Genetic polymorphisms associated with steroids metabolism and insulin action in polycystic ovary syndrome
}}

{{PMID Auto
|PMID=22418777
|Title=Estrogen-related genes and their contribution to racial differences in breast cancer risk
|OA=1
}}

{{PMID Auto
|PMID=22658813
|Title=Association Between Polymorphisms in COMT, PLCH1, and CYP17A1, and Non-Small-Cell Lung Cancer Risk in Chinese Nonsmokers
}}

{{PMID|17307805}} CYP17 genotype is associated with short menstrual cycles, early oral contraceptive use and BRCA mutation status in young healthy women.

{{PMID|17615053|OA=1
}} Polymorphisms in the cytochrome P450 genes CYP1A2, CYP1B1, CYP3A4, CYP3A5, CYP11A1, CYP17A1, CYP19A1 and colorectal cancer risk.

{{PMID|17986287}} The rs743572 common variant in the promoter of CYP17A1 is not associated with prostate cancer risk or circulating hormonal levels.

{{PMID|18006912}} CYP17 genetic variation and risk of breast and prostate cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3).

{{PMID|18163429|OA=1
}} Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men's Health Study.

{{PMID|18172694}} Genetic variation in CYP17 and endometrial cancer risk.

{{PMID|18437511|OA=1
}} Variants in hormone biosynthesis genes and risk of endometrial cancer.

{{PMID|18483327|OA=1
}} Polymorphisms in steroid hormone biosynthesis genes and risk of breast cancer and fibrocystic breast conditions in Chinese women.

{{PMID|18601603}} Polymorphisms of CYP17A1, CYP19, and androgen in Brazilian women with uterine leiomyomas.

{{PMID|18603647|OA=1
}} Functional genetic polymorphisms and female reproductive disorders: Part I: Polycystic ovary syndrome and ovarian response.

{{PMID|18628428|OA=1
}} Polymorphisms in genes involved in sex hormone metabolism, estrogen plus progestin hormone therapy use, and risk of postmenopausal breast cancer.

{{PMID|18629629}} Association of genetic polymorphisms of ER-alpha and the estradiol-synthesizing enzyme genes CYP17 and CYP19 with breast cancer risk in Chinese women.

{{PMID|18805939|OA=1
}} Functional genetic polymorphisms and female reproductive disorders: part II--endometriosis.

{{PMID|19015200|OA=1
}} Polymorphisms in estrogen- and androgen-metabolizing genes and the risk of gastric cancer.

{{PMID|19127255|OA=1
}} Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium.

{{PMID|19174490|OA=1
}} Tobacco and estrogen metabolic polymorphisms and risk of non-small cell lung cancer in women.

{{PMID|19387820|OA=1
}} Genetic polymorphisms of FSHR, CYP17, CYP1A1, CAPN10, INSR, SERPINE1 genes in adolescent girls with polycystic ovary syndrome.

{{PMID|19679043|OA=1
}} African American-preponderant single nucleotide polymorphisms (SNPs) and risk of breast cancer.

{{PMID|20171624}} Solitary and multiple uterine leiomyomas among Caucasian women: two different disorders?

{{PMID|20411041|OA=1
}} Common Variation in the CYP17A1 and IFIT1 Genes on Chromosome 10 Does Not Contribute to the Risk of Endometriosis.

{{PMID|20798986}} The CYP17A1 -34T > C polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers.

{{PMID|21229561}} CYP17 gene polymorphisms and prostate cancer risk: A meta-analysis based on 38 independent studies.

{{PMID|21644229}} [Association of single nucleotide polymorphism in CYP17 and ERalpha genes with endometriosis risk in southern Chinese women].

{{PMID|21656827}} CYP17 gene polymorphisms and prostate cancer risk: a meta-analysis based on 38 independent studies.

{{PMID Auto
|PMID=23129512
|Title=Polymorphisms in CYP17 and CYP3A4 and prostate cancer in men of African descent
|OA=1
}}

{{PMID Auto
|PMID=24430361
|Title=Genetic polymorphisms of ESR1, ESR2, CYP17A1, and CYP19A1 and the risk of breast cancer: a case control study from North India
}}

{{PMID Auto
|PMID=22714708
|Title=Genetic polymorphisms of CYP17A1 in steroidogenesis pathway are associated with risk of progression to castration-resistant prostate cancer in Japanese men receiving androgen deprivation therapy.
}}

{{PMID Auto
|PMID=23649771
|Title=Genetic variation of the CYP17 and susceptibility to endometrial cancer: a meta-analysis.
}}

{{PMID Auto
|PMID=23809139
|Title=Polymorphic variants of CYP17 and CYP19A and risk of infertility in endometriosis.
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}